pharmacie et médicaments – Accessibilité des traitements innovants contre le myélome multiple

This written question asks about how to ensure patients can access new and innovative treatments for multiple myeloma. It highlights concerns regarding the availability and affordability of these advanced therapies. The question seeks to understand the government's strategy for improving access to cutting-edge medicines, potentially impacting patients, healthcare providers, and pharmaceutical companies.